| Clinical characteristics and outcomes of COVID-19–infected cancer patients: a systematic review and meta-analysis H Zhang, H Han, T He, KE Labbe, AV Hernandez, H Chen, V Velcheti, ... JNCI: Journal of the National Cancer Institute 113 (4), 371-380, 2021 | 231 | 2021 |
| CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ... Cancer cell 37 (1), 37-54. e9, 2020 | 182 | 2020 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 173 | 2019 |
| Distinct prognostic factors in patients with stage I non–small cell lung cancer with radiologic part-solid or solid lesions F Fu, Y Zhang, Z Wen, D Zheng, Z Gao, H Han, L Deng, S Wang, Q Liu, ... Journal of Thoracic Oncology 14 (12), 2133-2142, 2019 | 163 | 2019 |
| Genomic and immune profiling of pre-invasive lung adenocarcinoma H Chen, J Carrot-Zhang, Y Zhao, H Hu, SS Freeman, S Yu, G Ha, ... Nature communications 10 (1), 5472, 2019 | 163 | 2019 |
| ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer J Deng, A Thennavan, I Dolgalev, T Chen, J Li, A Marzio, JT Poirier, ... Nature cancer 2 (5), 503-514, 2021 | 92 | 2021 |
| Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC KH Tang, S Li, A Khodadadi-Jamayran, J Jen, H Han, K Guidry, T Chen, ... Cancer discovery 12 (1), 47-61, 2022 | 73 | 2022 |
| Acyloxyacyl hydrolase promotes the resolution of lipopolysaccharide-induced acute lung injury B Zou, W Jiang, H Han, J Li, W Mao, Z Tang, Q Yang, G Qian, J Qian, ... PLoS pathogens 13 (6), e1006436, 2017 | 57 | 2017 |
| Recent advances in preclinical models for lung squamous cell carcinoma Y Pan, H Han, KE Labbe, H Zhang, KK Wong Oncogene 40 (16), 2817-2829, 2021 | 46 | 2021 |
| Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng, KH Tang, S Cao, ... Cancer research 81 (20), 5311-5324, 2021 | 44 | 2021 |
| KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition Y Pan, H Han, H Hu, H Wang, Y Song, Y Hao, X Tong, AS Patel, ... Cancer cell 41 (1), 88-105. e8, 2023 | 42 | 2023 |
| Selective lymph node dissection in early-stage non-small cell lung cancer H Han, H Chen Journal of thoracic disease 9 (7), 2102, 2017 | 38 | 2017 |
| Development and validation of a five‐gene model to predict postoperative brain metastasis in operable lung adenocarcinoma F Fu, Y Zhang, Z Gao, Y Zhao, Z Wen, H Han, Y Li, H Chen International journal of cancer 147 (2), 584-592, 2020 | 30 | 2020 |
| Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity H Hu, A Khodadadi-Jamayran, I Dolgalev, H Cho, S Badri, LA Chiriboga, ... Cancer Immunology Research 9 (11), 1298-1315, 2021 | 29 | 2021 |
| Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer Q Huang, F Li, H Hu, Z Fang, Z Gao, G Xia, WL Ng, ... Science advances 8 (5), eabi9533, 2022 | 28 | 2022 |
| Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis Y Yan, Q Huang, H Han, Y Zhang, H Chen Journal of cardiothoracic surgery 15, 1-9, 2020 | 26 | 2020 |
| Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies H Han, Y Zhao, H Chen Journal of Thoracic Disease 10 (6), 3428, 2018 | 15 | 2018 |
| Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer F Fu, Y Zhang, Z Gao, Y Zhao, Z Wen, H Han, Y Li, H Hu, H Chen Journal of Cancer Research and Clinical Oncology 147, 739-747, 2021 | 12 | 2021 |
| Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy Y Zhang, C Deng, X Ma, Z Gao, S Wang, Q Zheng, G Xia, Z Wen, H Han, ... Journal of Cancer Research and Clinical Oncology 146, 2411-2417, 2020 | 10 | 2020 |
| A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy H Han, Y Zhao, Z Gao, D Zheng, F Fu, Z Zhao, Y Tang, J Xiang, Y Sun, ... Journal of cancer research and clinical oncology 145, 2115-2122, 2019 | 10 | 2019 |
Kwok-Kin WongNYU Langone HealthBestätigte E-Mail-Adresse bei nyulangone.org